Glycophos

Glycophos is an intravenous solution that contains the active ingredient sodium glycerophosphate. It is supplied in a sterile liquid form for parenteral administration. As a phosphate supplement, Glycophos provides phosphate ions to support metabolic processes, ATP production, and bone mineralization. The product is marketed in the European Union and is available by prescription only.

Glycophos is used when patients require rapid restoration of phosphate levels or when phosphate is needed as part of parenteral nutrition. It is indicated for specific electrolyte replacement situations in clinical settings.

- Treatment of hypophosphatemia caused by inadequate intake, renal losses, or redistribution. - Supplementation of phosphate in total parenteral nutrition (TPN) regimens. - Support of patients undergoing major surgery or trauma with anticipated phosphate depletion. - Management of electrolyte imbalances in intensive care units. - Adjunct therapy during dialysis when phosphate removal is excessive.

Side effects of Glycophos may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common: - Local irritation at the infusion site. - Mild nausea or vomiting. - Transient headache. - Temporary elevation of serum calcium. - Mild hyperkalemia.

Serious: - Severe hyperphosphatemia leading to calcium-phosphate precipitation. - Acute renal failure due to phosphate overload. - Anaphylactic or severe hypersensitivity reactions. - Cardiac arrhythmias associated with electrolyte disturbances. - Metabolic acidosis in susceptible individuals.

When using Glycophos, clinicians should assess patient risk factors and monitor laboratory values closely. The following precautions are recommended:

- Verify baseline serum phosphate, calcium, and renal function before initiation. - Adjust dose in patients with chronic kidney disease or impaired renal clearance. - Avoid rapid infusion rates to reduce risk of precipitation and cardiovascular effects. - Monitor for signs of hyperphosphatemia, especially in patients receiving calcium supplements. - Use caution in pregnant or breastfeeding women; safety data are limited. - Discontinue if severe hypersensitivity or anaphylaxis occurs. - Ensure proper aseptic technique to prevent infection at the infusion site.

Glycophos may interact with other medications or solutions that affect phosphate or calcium balance. Consider the following when co‑administering:

Avoid: - Calcium-containing intravenous solutions administered simultaneously, which can cause calcium‑phosphate precipitation. - High-dose vitamin D analogues that increase intestinal phosphate absorption. - Loop diuretics that may exacerbate electrolyte shifts.

Use with caution: - Antacids containing aluminum or magnesium, which can bind phosphate. - Renin‑angiotensin‑aldosterone system inhibitors that affect renal phosphate handling. - Parathyroid hormone analogues influencing calcium‑phosphate metabolism. - Other electrolyte supplements (e.g., potassium, magnesium) that may compound serum abnormalities.